Japanese
Title99mTc-Teboroximeの臨床的有用性の評価 - 第III相多施設共同試験 -
Subtitle原著
Authors小塚隆弘1,*, 石田良雄2,**, 久保敦司4, 大嶽達3, 佐々木康人3, 藤森研司6, 古舘正従6, 小林毅7, 高橋恒男8, 柳澤融8, 中居賢司9, 盛合直樹10, 橋本順4, 橋本省三4, 岩永史郎5, 氏田万寿夫11, 森豊11, 川上憲司11, 島田孝夫12, 青木学13, 原田潤太13, 池田基昭14, 山崎純一14, 森下健14, 水野春芳15, 西村徹15, 田原順雄15, 石川恭三15, 伊藤健吾16, 佐久間貞行16, 大島統男17, 中嶋憲一18, 分校久志18, 久田欣一18, 山上英利1, 柏木徹1, 越智宏暢19, 秋岡要20, 佐々木雅之21, 桑原康雄21, 一矢有一21, 増田康治21, 濱本研22,***
Authors(kana)
Organization1大阪大学医学部放射線科, 2第一内科, 3東京大学医学部放射線科, 4慶應義塾大学医学部放射線科, 5呼吸循環器内科, 6北海道大学医学部核医学講座, 7循環器内科, 8岩手医科大学医学部放射線科, 9臨床検査医学科, 10第二内科, 11東京慈恵会医科大学放射線科, 12第三内科, 13附属柏病院放射線科, 14東邦大学医学部第一内科, 15杏林大学医学部第二内科, 16名古屋大学医学部放射線科, 17名古屋第一赤十字病院放射線科, 18金沢大学医学部核医学科, 19大阪市立大学医学部核医学研究室, 20第一内科, 21九州大学医学部放射線科, 22愛媛大学医学部放射線科, *:治験総括医師, **:論文執筆者, ***:コントローラー
Journal核医学
Volume29
Number12
Page1399-1417
Year/Month1992/12
Article原著
Publisher日本核医学会
Abstract「要旨」新しい心筋血流イメージング製剤である99mTc-Teboroximeの臨床的有用性について, 第III相多施設共同試験として, 冠動脈疾患を主体とした194例を対象にSPECTイメージング法を用いて検討した. SPECT撮像は, 早期撮像および撮像時間の短縮が重要で, 本剤の心筋クリアランスの半減期(約11分)以内での撮像が良好な画像を得る条件であると考えられた. 本撮像条件の下では, その心筋分布は血流分布をよく反映すると考えられ, 心筋分布の状態, 心筋梗塞および狭心症における陽性率, 運動負荷による冠動脈病変の診断精度は201Tlとほぼ一致した. 心筋viabilityの評価については, 201Tlとの間に優劣の判定が困難で今後の検討課題であると考えられた. 本剤は安全性に問題はなく, 総合的に評価された臨床的有用性は98.4%に認められ, 優れた心筋イメージング製剤であると結論された,
Practice臨床医学：一般
Keywords99mTc-Teboroxime, SPECT, Myocardial perfusion, 201Tl, Coronary artery disease.
English
TitleDiagnostic Value of a New Myocardial Perfusion Agent, 99mTc-teboroxime (SQ30, 217) in Patients with Coronary Artery Disease, Utilizing a SPECT Imaging Protocol : Multicenter Phase III Clinical Trial
SubtitleOriginal Articles
AuthorsTakahiro KOZUKA1, Yoshio ISHIDA2, Atsushi KUBO4, Tohru OTAKE3, Yasuhito SASAKI3, Kenji FUJIMORI6, Masayori FURUDATE6, Takeshi KOBAYASHI7, Tsuneo TAKAHASHI8, Toru YANAGISAWA8, Kenji NAKAI9, Naoki MORIAI10, Shozo HASHIMOTO4, Jun HASHIMOTO4, Shiro IWANAGA5, Masuo UJITA11, Yutaka MORI11, Kenji KAWAKAMI11, Manabu AOKI11, Junta HARADA11, Takao SHIMADA12, Motoaki IKEDA13, Junichi YAMAZAKI13, Takeshi MORISHITA13, Yorio TAHARA14, Haruyoshi MIZUNO14, Toru NISHIMURA14, Kyozo ISHIKAWA14, Kengo ITOH15, Sadayuki SAKUMA15, Motoo OSHIMA16, Kenichi NAKAJIMA17, Hisashi BUNKO17, Kinichi HISADA17, Hidetoshi YAMAGAMI1, Toru KASHIWAGI1, Hironobu OCHI18, Kaname AKIOKA19, Masayuki SASAKI20, Yasuo KUWABARA20, Yuichi ICHIYA20, Kouji MASUDA20, Ken HAMAMOTO21
Authors(kana)
Organization1Department of Radiology, 2First Department of Medicine, Osaka University Medical School, 3Department of Radiology, Faculty of Medicine, University of Tokyo, 4Department of Radiology, 5Department of Internal Medicine, School of Medicine, Keio University, 6Department of Nuclear Medicine, 7Department of Cardiovascular Medicine, Hokkaido University, School of Medicine, 8Department of Radiology, 9Department of Clinical Pathology, 10Second Department of Internal Medicine, Iwate Medical University, School of Medicine, 11Department of Radiology, 12Third Department of Medicine, Jikei University School of Medicine, 13First Department of Internal Medicine, Toho University School of Medicine, 14Second Department of Internal Medicine, Kyorin University, School of Medicine, 15Department of Radiology, Nagoya University, School of Medicine, 16Department of Radiology, Nagoya First Red Cross Hospital, 17Department of Nuclear Medicine, School of Medicine, Kanazawa University, 18Division of Nuclear Medicine, 19First Department of Internal Medicine, Osaka City University, Medical School, 20Department of Radiology, Faculty of Medicine, Kyushu University, 21Department of Radiology, Ehime University School of Medicine
JournalThe Japanese Journal of nuclear medicine
Volume29
Number12
Page1399-1417
Year/Month1992/12
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary]Technetium-99m teboroxime (TEBO) is a new technetium-based myocardial perfusion imaging agent, which has high myocardial extraction and rapid myocardial washout. Its rapid myocardial washout may necessiate rapid imaging protocols. This study was designed to perform exercise/rest SPECT imaging protocols with rapid data acquisition (from 2.8 +- 1.4 min to 11.2 +- 4.1 min after injection) in 171 patients with coronary artery disease, 15 patients with cardiomyopathy and 8 patients with other heart disease. The rapid imaging protocols resulted in a high prevalence of good image quality. The diagnostic value of TEBO was recognized from the high concordance of image findings with thallium-201 (201Tl) scintigraphy, 88.2% in the exercise protocol and 89.9% in the rest protocol. Also, the sensitivity and specificity of TEBO for detecting coronary artery disease were comparable (86.6% and 53.9%, respectively) with those of 201Tl (90.7% and 46.2%, respectively). No toxic effects of TEBO were observed in subjective and objective clinical findings and blood examinations. TEBO was finally evaluated to be useful in 98.4% of the patients. Thus, this agent has good clinical potential for myocardial perfusion imaging.
PracticeClinical medicine
Keywords99mTc-Teboroxime, SPECT, Myocardial perfusion, 201Tl, Coronary artery disease.

【全文PDF】